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Agonist-induced aggregation of Chinese hamster ovary cells coexpressing the
human receptors for fibrinogen (integrin aIIbb3) and the platelet-activating
factor: dissociation between adhesion and aggregation
Susana Larrucea, Consuelo Gonza´lez-Mancho´n, Nora Butta, Elena G. Arias-Salgado, Linnan Shen, Matilde S. Ayuso, and Roberto Parrilla
This work reports the establishment of a
Chinese hamster ovary (CHO) cell line
stably coexpressing the human aIIbb3
integrin and the platelet-activating factor
receptor (PAFR). These cells aggregate in
response to PAF in a Ca11, aIIbb3, and
soluble fibrinogen (Fg)–dependent man-
ner that is prevented by PAF antagonists
or aIIbb3 blockade. The aggregating re-
sponse is accompanied by enhanced bind-
ing of fibrinogen and the activation-depen-
dent IgM PAC1. This model has permitted
us to identify, for the first time, intracellu-
lar signals distinctly associated with ei-
ther aIIbb3-mediated adhesion or aggre-
gation. Nonreceptor activation of protein
kinase C (PKC) by phorbol ester pro-
duced cellular adhesion and spreading
onto immobilized Fg, but it was not a
sufficient signal to provoke cellular aggre-
gation. Moreover, inhibition of PKC im-
peded the PAF stimulation of cellular ad-
hesion, whereas the aggregation was not
prevented. The PAF-induced cellular ag-
gregation was distinctly associated with
signaling events arising from the ligan-
ded Fg receptor and the agonist-induced
stimulation of a calcium/calmodulin-
dependent signaling pathway. Sustained
tyrosine phosphorylation of both mitogen-
activated protein kinase (MAPK) and an
approximately 100-kd protein was associ-
ated with the PAF-induced aggregation,
whereas phosphorylation of focal adhe-
sion kinase (FAK) was preferably associ-
ated with cellular adherence and spread-
ing onto immobilized Fg. (Blood. 2002;99:
2819-2827)
© 2002 by The American Society of Hematology
Introduction
In addition to the role of platelet aggregation in maintaining a
normal hemostasis, recent evidence suggests that a platelet dysfunc-
tion might be involved in the etiopathogenesis of certain throm-
botic events.1,2 A prerequisite for platelet aggregation is the binding
of soluble fibrinogen (Fg) to cell-surface receptors. The noncova-
lent calcium-dependent heterodimer formed by glycoproteins (GP)
IIb and IIIa, integrin aIIbb3, expressed only in platelets and in
some tumor cells,3 is a receptor for Fg4 and other extracellular
matrix adherent proteins. Under normal resting conditions the Fg is
bound to the platelet aIIbb3 with low affinity. The binding of
platelets to exposed adherent proteins of the subendothelial ma-
trix5,6 and stimulation of G-protein–coupled surface receptors by
their agonists seem to bring out changes in the aIIbb3 ligand
avidity (receptor clustering) or affinity.7 It has been postulated that
activation of cellulifugal (“in-out”) signaling pathway(s) would
alter the conformation of aIIbb3, increasing its ligand binding
affinity.8 The activation of platelets is accompanied by a variety of
cellular responses, like increased metabolic activity, perturbation of
Ca11 and H1 homeostasis, increased adherence to extracellular
matrix proteins as well as to other cells, and changes in size, shape,
and motility related to association of the Fg receptor with the
cytoskeletal structures. Activation of PKC as well as distinct
patterns of tyrosine phosphorylation of intracellular protein have
also been reported to be associated with platelet activation.9,10 The
interrelationship of all the events taking place in activated platelets
as well as their relevance to the increased ligand affinity of aIIbb3
is not apparent. Thus, the elucidation of the mechanism(s) control-
ling platelet aggregation is hampered by the diversity of concomi-
tant responses. Investigation of the eventual activation of human
recombinant aIIbb3 expressed in established cell lines has been
attempted to circumvent this problem. However, to our knowledge,
full activation of reconstituted aIIbb3 receptors by physiologic
signals, as indicated by soluble Fg-dependent aggregation, has not
been yet demonstrated. Increased adherence to immobilized Fg has
been observed in lymphoblastoid cells transfected with aIIbb3
following postreceptor activation of PKC by phorbol 12-myristate
13-acetate (PMA) or by activation of a G-protein–coupled receptor
by the agonist formyl Met-Leu-Phe.11 Based on these observations,
it has been suggested that the intracellular signaling pathway
involved in aIIbb3 activation could be specific for hematopoietic
cells. However, PMA-induced stimulation of adherence of Chinese
hamster ovary (CHO) cells expressing aIIbb3 to immobilized Fg
has also been observed.12 A recent report indicates that the ligand
occupancy of the GPIb-IX complex, a receptor for the von
Willebrand factor (VWF), coexpressed in CHO cells along with the
aIIbb3 complex, enhanced cell adherence to immobilized Fg.13
Because no cell aggregation was reported, it cannot be ascertained
whether signaling through the VWF receptor was a sufficient signal
to achieve full aIIbb3 activation in transfected CHO cells. On
these grounds, we hypothesized that a full aIIbb3 receptor
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activation and, therefore, Fg-dependent aggregation of CHO cells,
could be achieved if the proper signaling pathway was stimulated.
In this regard, since CHO cells do not express any of the
G-protein–coupled receptors known to mediate agonist activation
of platelets, we consider it of interest to investigate the eventual
agonist-induced activation of aIIbb3 in CHO cells coexpressing a
receptor for a physiologic agonist.
This work reports the development of a CHO cell model stably
coexpressing the human platelet-activating factor (PAF) receptor
(PAFR) and the Fg receptor (aIIbb3). PAF elicits an aIIbb3-
mediated stimulation of adherence of these cells to immobilized
Fg. Moreover, we observed agonist-initiated, soluble Fg, and
aIIbb3-dependent cellular aggregation, indicative of full Fg
receptor activation. This model has allowed us to differentiate,
for the first time, intracellular signaling pathways and patterns
of tyrosine phosphorylation of proteins distinctly associated
with agonist-induced stimulation of aggregation in a reconsti-
tuted aIIbb3 system.
Materials and methods
Antibodies and reagents
A monoclonal antibody (mAb) specific for b3 was the gift of Drs J.
Gonza´lez and M. V. Alvarez from the Institute Rocasolano (CSIC), Madrid,
Spain. The anti-aIIb mAb 2bc1 was produced by standard techniques and
purified by affinity chromatography with the recombinant extracellular
fragment of aIIb. Phospho-specific p44/42 MAPK antibody was obtained
from New England Biolabs (Beverly, MA). Polyclonal anti-FAK antibody
and antiphosphotyrosine mAb PY99 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Polyclonal anti–human PAFR was
provided by Dr M. Rola-Pleszczynski (University of Sherbrooke, QC
Canada). Antiphosphotyrosine mAb 4G10 agarose conjugate was from
Upstate Biotechnology (Lake Placid, NY), fluorescein isothiocyanate
(FITC)–labeled mAb PAC1 was from Becton Dickinson (San Jose, CA),
and FITC-conjugated F(ab’)2 fragment of rabbit anti–mouse Ig was from
Dako A/S (Glostrup, Denmark). The horseradish peroxidase (HRP)–
conjugated secondary goat anti–mouse Ig and goat anti–rabbit Ig were from
Bio-Rad Laboratories (Hercules, CA) and Sigma-Aldrich (Madrid, Spain),
respectively.
Platelet-activating factor-16 (PAF 1-O-alkyl-2-acetyl-sn-glycero-3-
phosphocoline) and PAF antagonist were obtained from Calbiochem (La
Jolla, CA). Mitogen-activated protein kinase (MAPK) kinase inhibitor
(PD98059), phosphatidylinositol 3-kinase (PI 3-K) inhibitor (LY294002),
Arg-Gly-Asp-Ser (RGDS) and Arg-Gly-Glu-Ser (RGES) peptides, pertus-
sis toxin (PTX), human fibrinogen (fraction I, type I), PMA, PKC inhibitors
(H7 and staurosporine), Ca11-calmodulin pathway antagonist (W7), intra-
cellular Ca11 chelator (BAPTA-AM), Na1/H1 exchanger inhibitor (EIPA),
tyrosine protein kinase inhibitor (genistein), bisindolylmaleimide I (BIM-I),
and dibutyryl cAMP (db-cAMP) were purchased from Sigma-Aldrich.
Establishment and characterization of CHO cell lines stably
expressing aIIbb3 integrin and/or the platelet-activating
factor receptor
CHO cell lines stably expressing b3 (CHO-b3 cells) or aIIbb3 complex
(CHO-aIIbb3 cells) were established as described previously.14 CHO,
CHO-b3, and CHO-aIIbb3 cells were transfected with 15 mg human PAFR
cDNA subcloned in the expression vector pcDNA3 (Invitrogen, San Diego,
CA), using the calcium phosphate precipitation procedure. The transfected
cells were fed with medium containing 800 mg/mL G-418 every 3 to 4 days,
and clones of cells stably expressing PAFR were selected by monitoring the
effect of PAF on intracellular pH and calcium mobilization, as previously
described.15,16 Expression of PAFR on stably transfected cells was also
assessed by Western blot analysis.17
Adhesion of CHO cell lines to immobilized Fg
96-well flat-bottomed plates were coated with 10 mg/mL Fg in phosphate
buffered saline (PBS) pH 7.2 (100 mL per well) for 2 hours at 37°C and then
washed with PBS, blocked with 200 mL of 1% bovine serum albumin
(BSA) for 1 hour at 37°C, and washed with PBS. CHO cell lines growing in
Dulbecco modified Eagle medium (DMEM) containing 10% fetal bovine
serum were harvested by ethylenediaminetetraacetic acid (EDTA) treat-
ment, collected by centrifugation, and resuspended in serum-free DMEM.
Then, they were labeled with 10 mM calcein-AM (Molecular Probes,
Leiden, The Netherlands) for 10 minutes, washed by centrifugation, and
activated with 100 nM PAF for 2 minutes at room temperature. Then, they
were plated onto dishes, in duplicate, at a density of 4 3 104 cells/well, in
DMEM, and incubated for different periods of time at 37°C. Nonadherent
cells were removed by carefully washing twice with 200 mL PBS. Cell
adhesion was quantitated by cytofluorimetry. To calculate the percentage of
attachment, basal adherence to BSA (cell binding to BSA-coated wells was
always , 1%) was subtracted from attachment values. In some experi-
ments, labeled cells were preincubated with inhibitors, which had no effect
on cell viability. At the end of the assays, adherent cells were examined with
a phase-contrast Nikon TMS microscope and micrographs were taken with
a digital camera.
Soluble Fg-dependent aggregation of CHO cell lines
Cells growing in DMEM containing 10% fetal bovine serum were
harvested by EDTA treatment, collected by centrifugation, and resuspended
in serum-free DMEM. After 30 minutes at 37°C, they were incubated with 1
mg/mL Fg for 15 minutes at room temperature at a density of 2.5 3 106
cells/mL. Then, PAF was added and 250 mL cell suspension was plated onto
wells of a 24-well culture dish precoated with 1 mg/mL BSA. In some
experiments, cells were activated for 2 minutes with PAF prior to Fg
addition. When indicated, cells were pretreated with inhibitors before Fg
incubation. Approximately 10 to 15 minutes after plating, cell aggregates
were examined by phase-contrast microscopy as above.
For flow cytometric assessment of aggregation, cells were fixed with
0.25% paraformaldehyde during 30 minutes at room temperature, and
forward (FS) and side (SS) light scatter data from 10 000 events were
collected in a linear mode. FS is related to the size of the analyzed particles
and is an index of cell aggregate formation.
Flow cytometry analysis of PAC1 binding
CHO-aIIbb3-PAFR cells (2.5 3 106 cells/mL) were resuspended in Tyrode
buffer and incubated at 22°C for 15 minutes with FITC-PAC1, in the
presence or absence of 100 nM PAF. Then, cells were fixed with 0.25%
paraformaldehyde and binding was analyzed by flow cytometry.
Fibrinogen binding to CHO-aIIbb3-PAFR cells
FITC-labeling of Fg was performed as described previously.18 A quantity of
8 3 105 cells were incubated with FITC-Fg (0 mM-7 mM) at 22°C for 15
minutes, in the presence or absence of 100 nM PAF, in a final volume of 150
mL. Then, cells were collected by centrifugation through a layer of 20%
sucrose, and lysed in buffer containing 1% Triton X-100. The bound
fluorescence was quantified in a microplate fluorescence reader (PolarStar
Galaxy, BMG Lab Technologies, Offenburg, Germany). The effect of
different inhibitors on the PAF-induced Fg binding was assayed at
saturating Fg concentration. Nonspecific Fg binding was determined in
parallel assays in the presence of 10 mM EDTA or 2 mM RGDS.
Antiphosphotyrosine immunoblot assay
Adherent or aggregating cells were washed with PBS supplemented with 30
mM sodium pyrophosphate, 50 mM sodium fluoride, and 100 mM sodium
orthovanadate and then lysed in 50 mL to 100 mL ice-cold urea buffer (8 M
urea, 4% CHAPS, 1% Triton X-100, 200 mM DTT, 1 mM sodium
orthovanadate, 1 mM sodium fluoride, 1 mM sodium pyrophosphate, 2 mM
EDTA, 40 mM Tris pH 7.5). Nonadherent cells were washed by centrifuga-
tion and lysed as before. Lysates were cleared by centrifugation (13 000g,
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15 minutes), and proteins (50 mg) were separated on 6% to 16% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) under
reducing conditions and electrotransferred onto polyvinylidenefluoride
(PVDF) membranes. Membranes were incubated for 1 hour in blocking
buffer (1% BSA in 10 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween 20) and
then in the same buffer containing a 1:500 dilution of the antiphosphoty-
rosine mAb PY99 for 1 hour. After washing, the membranes were incubated
with HRP-conjugated anti–mouse Ig diluted 1:3000 for 1 hour, washed, and
the bound antibody was visualized using the enhanced chemiluminescence
(ECL) detection procedure.
Tyrosine phosphorylation of b3
At various times after PAF stimulation, cells were resuspended in PBS
buffer, lysed using a Branson Sonifier 450 Sonicator (Branson, Danbury,
CT), and pelleted by ultracentrifugation at 80 000g for 30 minutes. Pellets
were extracted on ice with either radioimmunoprecipitation assay (RIPA)
buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 158 mM
NaCl, 1 mM EDTA, 10 mM Tris-HCl pH 7.2), or with a modified RIPA
buffer (1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM
EGTA, 50 mM Tris-HCl pH 7.4), supplemented with 25 mL/mL protease
inhibitor cocktail (Sigma) and 4 mM phosphatase inhibitors (sodium
orthovanadate, sodium fluoride, and sodium pyrophosphate). A quantity of
0.5 mg protein lysate was incubated with the anti-b3 mAb P37 followed by
precipitation with protein A-sepharose beads. Beads were then washed 4
times with lysis buffer, and the precipitates recovered by boiling the beads
in 40 mL SDS sample buffer (90 mM Tris-HCl pH 6.8, 3.2% SDS, 10%
glycerol, 160 mM DTT, 0.4 mg/mL bromophenol blue). Immunoprecipi-
tates were resolved by SDS-PAGE and transferred onto PVDF membranes.
Tyrosine phosphorylation of immunoprecipitated b3 was analyzed by
immunoblot with PY99 mAb as described above.
Tyrosine phosphorylation of b3 was also determined by using the
agarose-conjugated antiphosphotyrosine mAb 4G10 to precipitate tyrosine-
phosphorylated proteins, followed by immunoblot analysis of the immuno-
precipitates with P37 mAb.
Immunoblot analysis of phosphorylated FAK and MAPK
Cells were lysed in modified RIPA buffer and immunoprecipitation of FAK
was performed using a polyclonal anti-FAK antibody. Tyrosine phosphory-
lation of FAK was assessed by immunoblotting with antiphosphotyrosine
mAb PY99 of either immunoprecipitates or total cell lysates, as described
above. Identification of the phosphorylated MAPK in stimulated cells was
assessed by immunoblot with a phospho-specific p44/42 MAPK antibody.
Results
PAF-induced stimulation of adherence of CHO-aIIbb3-PAFR
cells to immobilized fibrinogen
CHO cells or CHO cells stably expressing the human Fg receptor
(CHO-aIIbb3) or the b3 subunit (CHO-b3) were stably transfected
with the PAF receptor. The features of the CHO-aIIbb3 cells have
been previously reported.14 The level of expression of PAFR was
assessed by immunochemical and functional criteria. Western
blotting with anti-PAFR revealed the presence of a band of the
expected size in human platelets or CHO-aIIbb3-PAFR cells but
not in CHO-aIIbb3 cells (Figure 1A). PAF induced an acute and
transient elevation of cytosolic-free Ca11 and intracellular alkaliza-
tion in CHO-PAFR or CHO-aIIbb3-PAFR cells that were pre-
vented by a PAF antagonist (Figure 1B-C). The ability of PAF to
increase the level of cytosolic-free calcium in the presence of 5 mM
EGTA suggests that this agonist mobilizes calcium primarily from
intracellular stores.19 The CHO-aIIbb3-PAFR cells express
3.1 3 106 aIIbb3 receptors per cell as determined by the binding of
the FITC-labeled anti-aIIb 2bc1.
Figure 2A depicts the effect of PAF in enhancing the rate of
adhesion and spreading of CHO-aIIbb3-PAFR cells onto Fg-
coated plates, an effect that was accompanied by the appearance of
focal adhesion complexes and the formation of actin stress fibers
(results not shown). This effect of PAF was clearly appreciated 5 to
10 minutes after seeding, whereas a similar degree of adhesion and
spreading in the absence of agonist was observed at 30 minutes.
Preincubation with increasing concentrations of soluble Fg pro-
duced a dose-dependent inhibition of the PAF stimulation of
adherence, whereas it was ineffective in nonstimulated cells
(results not shown). The effect of PAF in stimulating cell adherence
was observed only in cells coexpressing PAF and Fg receptors
(Figure 2B). On the other hand, nonstimulated CHO-aIIbb3 cells
adhered to Fg-coated plates, whereas CHO cells transfected with
void plasmids or CHO cells coexpressing PAFR and the b3 chain
of the Fg receptor (CHO-b3-PAFR cells) did not. These data
suggest that PAF stimulates cellular adhesion and spreading
through activation of aIIbb3.
Because Gi proteins have been involved in the agonist-induced
stimulation of aIIbb3,20 we investigated the effect of PTX on the
PAF-induced stimulation of cellular adherence. The stimulatory
effect of PAF on cell adhesion was partially inhibited by PTX,
suggesting that signaling through a Gi protein may be involved in
this process. Receptors linked to G proteins stimulate PKC through
Figure 1. Detection and characterization of PAFR stably transfected in CHO-
aIIbb3 cells. (A) Cell extracts were subjected to Western blotting analysis using a
rabbit polyclonal anti-PAFR. The arrow points to a band of the expected size of PAFR
that is present in human platelets and CHO-aIIbb3-PAFR cells, but absent in
CHO-aIIbb3 cells transfected with the void plasmid. (B) and (C) depict the effects of
PAF in increasing the intracellular cytosolic levels of free calcium and intracellular pH,
and the effect of a PAF antagonist in preventing both effects. Measurement of
intracellular calcium and pH was carried out fluorimetrically as described in “Materials
and methods.” The data are representative of at least 6 observations made in
different cell preparations.
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elevation of cytosolic-free Ca11 and/or diacylglycerol21; therefore,
we tested the effect of PKC inhibitors on the PAF-induced
stimulation of cellular adherence. The 3 agents tested inhibited the
effect of PAF, although staurosporine and the more specific
inhibitor BIM-I produced a more complete inhibition than H7
(Figure 3).
PAF-induced, soluble Fg-dependent aggregation of
CHO-aIIbb3-PAFR cells
A distinct feature of the CHO-aIIbb3-PAFR cells in suspension is
their ability to undergo soluble Fg-dependent aggregation upon
stimulation with PAF. This effect of PAF was not observed in CHO
cells expressing only PAF or Fg receptor (Figure 4). The aggregat-
ing response was also demonstrable by flow cytometry (Figure 5)
ruling out a subjective visual appreciation of the number of
aggregates. These observations indicate that CHO cells possess the
intracellular machinery needed to support a cross talk between PAF
and aIIbb3 recombinant receptors enabling the soluble fibrinogen-
dependent cell aggregation. This assertion is further supported by
the following observations: (1) the effect of PAF in enhancing cell
adherence was selectively prevented by soluble Fg in a dose-
dependent manner (results not shown); (2) the RGDS ligand
mimetic peptide prevented the PAF-induced aggregation while the
RGES did not (results not shown); and (3) antagonists of PAF,
destabilization of the aIIbb3 complex by EDTA, or a mAb directed
against b3 all prevented the PAF-induced aggregation, while an
irrelevant antibody did not (results not shown).
To assess the specificity of the PAF-induced aggregating
response, we measured the binding of Fg and the activation-
specific antibody PAC1 to CHO-aIIbb3-PAFR cells. Figure 6A
shows the FITC-Fg–binding isotherms in cells incubated with or
without PAF. The aIIbb3-dependent Fg binding was assessed by
subtracting the fluorescence bound to cells treated with 10 mM
EDTA. Exposure of cells to PAF led to a pronounced increase in the
amount of Fg bound to the cells. Near saturation ligand binding was
observed at approximately 4 mM Fg, which is within its physi-
ologic range of plasma concentration. The dissociation constant
(Kd) for Fg binding calculated by scatchard plot (Figure 6A, insert)
was 2 mM. Taking into account that one molecule of Fg may bind 2
receptors, our results suggest that in PAF-stimulated cells all the
aIIbb3 receptor ligand sites would be occupied. The effect of PAF
was also accompanied by a noticeable binding of the activation-
dependent IgM PAC1 (Figure 6B).
The stimulation of PKC by PMA enhanced the adhesion of
CHO-aIIbb3-PAFR cells to immobilized Fg but it failed to induce
cellular aggregation (results not shown). This observation implies
that postreceptor activation of PKC is not a sufficient signal to
promote cell aggregation. It also suggests that PAF-induced
aggregation relies on a signaling event or events upstream of PKC
activation. This assertion is supported by the lack of effect of PKC
inhibitors, such as staurosporine, H7, or BIM-1, in preventing the
PAF-induced cell aggregation and Fg binding to CHO-aIIbb3-
PAFR cells (Table 1). The elevation of cytosolic-free Ca11 and
Figure 3. Effect of PTX and PKC inhibitors on the effect of PAF in stimulating
the adherence of CHO-aIIbb3-PAFR cells to immobilized Fg. (A) CHO-aIIbb3-
PAFR cells were incubated with 200 ng/mL PTX for 2 hours at 37°C and then
stimulated with 100 nM PAF for 2 minutes. Cell adhesion to immobilized Fg at 10
minutes was measured as described in “Materials and methods.” To determine the
effect of inhibiting PKC on the PAF-stimulated adhesion to immobilized Fg, cells were
preincubated at 37°C with the indicated concentration of staurosporine (B) for 1 hour,
H7 (C) for 45 minutes, or bisindolylmaleimide-I (BIM-I) for 30 minutes (D). The data
are expressed relative to the adhesion of PAF-stimulated cells in the absence of
inhibitor and are means 6 SD of at least 3 experiments.
Figure 2. Effect of PAF on adhesion of CHO-aIIbb3-PAFR cells to immobilized
Fg. (A) Time course of the effect of PAF on adhesion of CHO-aIIbb3-PAFR cells to
immobilized Fg. CHO cells (4 3 105) coexpressing aIIbb3 and PAFR were added to
the wells of microtiter plates coated with 10 mg/mL Fg, incubated for different periods
of time at 37°C in the presence or absence of 100 nM PAF, and visualized by phase
contrast microscopy. (B) Comparative effect of PAF on adhesion of CHO, CHO-b3-
PAFR, CHO-aIIbb3, and CHO-aIIbb3-PAFR cell lines to immobilized Fg. Cells were
allowed to adhere on Fg-coated wells for 5 minutes, in the absence or presence of
100 nM PAF.
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activation of phospholipases are events distinctly associated with
the activation of G-protein–linked surface receptors.21 To deter-
mine whether a perturbation of Ca11 homeostasis was involved in
the PAF-induced cellular aggregation, we examined the effect of
the calcium-calmodulin inhibitor W7 or the intracellular calcium
chelator BAPTA. In both instances, the PAF-induced aggregation
of CHO-aIIbb3-PAFR cells was prevented and the Fg binding
impeded (Table 1).
Table 1 summarizes the effect of several agents on the
PAF-induced stimulation of cell adhesion, aggregation, and Fg
binding. A PAF antagonist prevented both adhesion and aggrega-
tion. Similar effects were observed by perturbing the state of
Figure 4. Soluble Fg-dependent aggregation of CHO-aIIbb3-PAFR cells in-
duced by PAF. Cells (2.5 3 106/mL) were incubated with 1 mg/mL Fg for 15 minutes
at room temperature in a 250 mL final volume and then stimulated with 100 nM PAF
and plated onto BSA-precoated wells. Aggregate formation was examined by
phase-contrast microscopy as described in “Materials and methods.” Original
magnification, 3 100.
Figure 5. Flow cytometric assessment of the PAF-induced aggregation of
CHO-aIIbb3-PAFR cells. Either CHO-aIIbb3-PAFR (A) or CHO-aIIbb3 cells
(B) (2.5 3 106/mL) were incubated for 15 minutes with soluble Fg (0.5 mg/mL) in the
presence or absence of 100 nM PAF and then fixed with 0.25% paraformaldehyde.
Forward (FS) and side (SS) light scatter data of each sample were analyzed by flow
cytometry as described in “Materials and methods.”
Figure 6. Effect of PAF on binding of soluble Fg or PAC1 to CHO-aIIbb3-PAFR
cells. (A) Binding of FITC-Fg to CHO-aIIbb3-PAFR cells. Cells were incubated for 15
minutes with soluble FITC-Fg, in the presence or absence of 100 nM PAF, as
described in “Materials and methods.” The data are means of 3 independent
experiments performed in duplicate. The insert shows the Scatchard plot of data.
(B) The histograms represent the expression of PAC1 binding sites in cells incubated
with or without 100 nM PAF.
Table 1. Differential effect of several treatments on the agonist-induced
aggregation, adhesion, and fibrinogen binding to CHO cells
coexpressing the human PAF and fibrinogen receptors
Aggregation Adhesion Fg binding (%)
PAF ant (200 nM) 2 2 ND
PTX (200 ng/mL) 1 2 ND
RGDS (1 mM) 2 2 0
H7 (25 mM) 1 2 75
Staurosporine (0.5 mM) 1 2 73
BIM-I (1 mM) 1 2 91
EDTA (5 mM) 2 2 0
W7 (20 mM) 2 1 22
BAPTA-AM (100 mM) 2 1 0
Genistein (100 mM) 1 1 100
PD98059 (50 mM) 1 1 ND
Ly294002 (20 mM) 1 1 ND
db-cAMP (500 mM) 1 1 ND
The effect of the different agents on the PAF-induced aggregation and adhesion
of CHO-aIIbb3-PAFR cells was assessed as described in “Materials and methods.”
Positive (1) or negative (2) signs indicate the presence or absence of adhesion or
aggregation. Fibrinogen binding is expressed as percent of the Fg bound to
PAF-stimulated cells in the absence of antagonists.
CHO indicates Chinese hamster ovary; PAF, platelet-activating factor; PAF ant,
PAF antagonist; PTX, pertussis toxin; RGDS, Arg-Gly-Asp-Ser; EDTA, ethylenedi-
aminetetraacetic acid; ND, not determined.
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association of the aIIbb3 heterodimer by EDTA or by the presence
of the ligand mimetic peptide RGDS. A parallel seems to exist
between the Fg-binding and cell-aggregating responses. Data in
Table 1 suggest that the PAF-induced aggregation is a process
selectively regulated by the Ca11 signaling pathway, whereas the
agonist-stimulation of cell adherence is controlled by the state of
activation of PKC.
PAF-induced tyrosine phosphorylation of proteins
Signaling through aIIbb3 is accompanied by tyrosine phosphoryla-
tion of proteins,9,10 and tyrosine kinase inhibitors prevent agonist-
induced platelet aggregation.22 Thus, we studied whether the
PAF-induced activation of aIIbb3 was accompanied by tyrosine
phosphorylation of specific proteins. Data in Figure 7 show the
antiphosphotyrosine reactivity of proteins from the indicated cell
lines. PAF induced the phosphorylation of 2 proteins of approxi-
mately 100 kd and approximately 44 kd. The 100-kd protein is
exclusively phosphorylated in cells expressing PAFR and, there-
fore, we will refer to it as the protein phosphorylated by agonist
(p100-PPA). The PAF-induced phosphorylation of p100-PPA is
more intense in CHO-aIIbb3-PAFR than in CHO-b3-PAFR cells
and is enhanced by the presence of Fg, suggesting an interaction
between the PAF-stimulated signaling pathway and the Fg receptor.
The 44-kd protein was identified as an isoform of the MAPK after
immunoblotting with phospho-specific p44/42 MAPK antibody.
Interaction with Fg phosphorylated MAPK in CHO-aIIbb3 cells,
whereas either PAF or Fg exerted a similar effect in CHO-aIIbb3-
PAFR. The effect of Fg builds up slowly and is maximal after at
least 15 minutes of incubation (Figure 8A). A half-maximal effect
of Fg was observed at a concentration of at least 100 mg/mL. The
effects of Fg and PAF in activating MAPK were synergic (Figure
8B). The PAF-induced phosphorylation of p100-PPA and MAPK
was observed in either aggregating or adherent cells; however, in
adherent cells the effect was transient and much less intense
(results not shown).
Based on the differential effect of PMA on adhesion or
aggregation, we studied its effects in phosphorylating p100-PPA
and MAPK. Figure 9 shows that PMA induced the phosphorylation
of MAPK but not the phosphorylation of p100-PPA in CHO-aIIbb3-
PAFR cells, giving further support to the relationship between the
activation of the PAF receptor and phosphorylation of p100-PPA.
In the absence of Fg, PMA failed to induce a significant phosphor-
ylation of MAPK. These observations seem to indicate that both
Figure 7. Tyrosine phosphorylation induced by PAF in CHO cell lines. Cells
(2.5 3 106/mL) were incubated with 1 mg/mL Fg for 15 minutes at room temperature
in a 250 mL final volume and then stimulated with 100 nM PAF and plated onto
BSA-precoated wells. After 15 minutes, cells were lysed and proteins (50 mg) were
separated by 6% to 16% SDS-PAGE, transferred to PVDF sheets and probed with
antiphosphotyrosine mAb PY99, as described in “Materials and methods.” The
arrows point to phosphorylated p100-PPA and MAPK proteins.
Figure 8. Time course of Fg and/or PAF-induced tyrosine phosphorylation of
proteins in CHO-aIIbb3-PAFR cells. (A) Cells (2.5 3 106/mL) were incubated with
100 nM PAF for 2 minutes at room temperature in a 250 mL final volume and then Fg
was added at 1 mg/mL and cells were plated onto BSA-precoated wells. (B) Cells
were incubated with 1 mg/mL Fg for 15 minutes at room temperature in a 250 mL final
volume and then stimulated with 100 nM PAF and plated onto BSA-precoated wells.
At the indicated times, cells were lysed and proteins (50 mg) were resolved by
SDS-PAGE, transferred to PVDF membranes and probed with antiphosphotyrosine
mAb PY99, as described in “Materials and methods.” The arrow points to the
phosphorylated MAPK protein. The densitometric analysis was carried out using the
public domain program NIH Image (http://rsb.info.nih.gov/nih-image/).
Figure 9. Differential effects of PAF and PMA on tyrosine phosphorylation of
p100-PPA and MAPK in CHO-aIIbb3-PAFR cells. Cells were incubated with either
100 nM PAF for 2 minutes or 100 nM PMA for 30 minutes. Then 1 mg/mL Fg was
added and cells were plated onto BSA-precoated wells. After 15 minutes, cells were
lysed and proteins (50 mg) were resolved by SDS-PAGE, transferred to PVDF
membranes, and probed with antiphosphotyrosine mAb PY99, as described in
“Materials and methods.”
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PMA and PAF enhanced the Fg-mediated phosphorylation of
MAPK. The ligand mimetic peptide RGDS neither stimulates nor
potentiates the PAF-induced phosphorylation of MAPK. Neither
genistein nor inhibitors of PKC alter the PAF-induced pattern of
protein phosphorylation. In contrast, the calmodulin inhibitor W7
prevented the agonist-induced phosphorylation of both p100-PPA
and MAPK and a similar but less intense effect was also produced
by the intracellular calcium chelator BAPTA (data not shown). All
other agents listed in Table 1 had no significant effects on the
PAF-induced tyrosine phosphorylation of proteins.
Effect of PAF in inducing the phosphorylation of either the
carboxyterminal end of b3 or FAK
It has been suggested that phosphorylation of the carboxyterminal
end of b3 could play a role in determining the functional state of
the aIIbb3 complex.23 Immunoprecipitation with anti-b3 (P37)
followed by blotting with antiphosphotyrosine or immunoprecipita-
tion with antiphosphotyrosine followed by blotting with anti-b3
(P37) did not show differences in the phosphorylation state of b3 in
CHO-aIIbb3-PAFR cells with or without PAF stimulation. This
observation agrees with the finding that mutations of tyrosine
residues in the cytosolic end of b3 did not prevent the platelet
aggregation in mice.24
Focal adhesion kinase (FAK) is a 125-kd protein that becomes
tyrosine phosphorylated in activated platelets. The phosphorylation
of FAK was 4- to 5-fold higher in adherent than in aggregating
CHO-aIIbb3-PAFR cells (Figure 10, upper panel). In cell suspen-
sions, PAF induced a phosphorylation of FAK within a minute of
exposure to the agonist (Figure 10, middle panel). The intensity of
this response was scarce and lasted less than 5 minutes. Adherent
cells showed a rapid phosphorylation of FAK after cells seeding
over an Fg-coated plate. The phosphorylation of FAK lasted for
at least one hour and it was enhanced by PAF (Figure 10, lower
panel). Thus, a correlation appears to exist between the phos-
phorylation of FAK and the PAF-induced adherence and spreading
of cells.
Discussion
Agonist-induced activation of CHO cells expressing human
recombinant aIIbb3
As far as we know, attempts to reconstitute full functional human
Fg receptors in established cell lines have not been totally
successful. However, coexpression of aIIbb3 with either the
receptor for the agonist formyl Met-Leu-Phe (fMLP), or with the
von Willebrand factor receptor, GPIb-IX complex, demonstrated
that ligation of these receptors could influence the state of
activation of aIIbb3.11,13 The present study shows that the aIIbb3
receptor can be fully activated by signals arising from liganded
PAF receptors in CHO cells. The lack of effect of PAF on cell lines
not expressing the PAF receptor (CHO or CHO-aIIbb3 cells), and
the inhibitory effects of PAF antagonists or aIIbb3 blockade,
support the specificity of the aIIbb3 “activation.” To our knowl-
edge, this is the first time that agonist-induced, soluble Fg-
dependent aggregation of nonhematopoietic cells is demonstrated.
The effect of PAF in activating aIIbb3 was accompanied by
enhanced binding of soluble fibrinogen and the activation-
dependent IgM PAC1, suggesting that PAF may induce cell
aggregation through conformational changes in aIIbb3. Calcula-
tions based on the number of receptors and the kinetics of ligand
binding indicate that PAF activation led to the occupancy of
virtually all the Fg receptors in CHO-aIIbb3-PAFR cells.
Our cell model has permitted the functional dissection of
agonist-induced adhesive and aggregating responses and the identi-
fication of signaling events distinctly associated with each process.
The PAF-induced cell aggregation was observed even though
inhibitors of PKC prevented the stimulation of cell adherence to
immobilized Fg. Conversely, the PAF-induced stimulation of cell
adherence was not impeded when inhibitors of the calcium-
calmodulin signaling pathway prevented the aggregating response.
The physiologic significance of these findings is supported by the
observation that inhibitors of Ca11-calmodulin prevented the
PAF-induced stimulation of Fg binding to human platelets while
the inhibitors of PKC did not (results not shown). A precedent of
apparent dissociation between the agonist-induced stimulation
of adherence and aggregation is implicit in the reported effect of
thrombin in stimulating the adherence but not the aggregation
of megakaryoblastic cells.25
Figure 10. Time course of PAF-induced tyrosine phosphorylation of FAK in
CHO-aIIbb3-PAFR cells in the presence of either soluble or solid-phase Fg. In
aggregation assays, cells were incubated with 1 mg/mL Fg for 15 minutes at room
temperature and then were stimulated with 100 nM PAF and plated onto BSA-
precoated wells. At the indicated times, cells were lysed and immunoprecipitation of
FAK was performed using a polyclonal anti-FAK antibody. Immunoprecipitates were
analyzed by immunoblotting with antiphosphotyrosine mAb PY99, as described in
“Materials and methods.” In adhesion experiments, cells were added to Fg-coated
wells and allowed to adhere for 15 minutes. Then 100 nM PAF was added and
incubation continued until the indicate times. Cells were lysed and tyrosine phosphor-
ylation of FAK was determined as above. The densitometric analysis was carried out
using the public domain program NIH Image (http://rsb.info.nih.gov/nih-image/).
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Mechanism(s) of PAF-induced activation of aIIbb3
Liganded PAFR are known to initiate Gi-sensitive and -insensitive
signaling events. Platelets deficient in Gaq fail to aggregate in
response to agonists26 and the thrombin receptor is coupled to
Gai.27 Thus, it seems plausible to assume that PAF may control the
state of activation of aIIbb3 through G-protein–coupled processes
in CHO-aIIbb3-PAFR cells. The herein reported results suggest
that PAF may alter the state of activation of aIIbb3 in a dual way:
first, enhancing the adherence of cells to immobilized Fg in a PTX-
and PKC-dependent manner; and second, in cell suspensions PAF
enhances the binding of soluble Fg and PAC1, with the result of
Ca11-calmodulin–dependent and PKC-independent cell aggrega-
tion. In this regard, the lack of effect of PTX on the PAF-induced
aggregation is consistent with its failure to prevent the mobilization
of Ca11 and phosphoinositides hydrolysis (results not shown).19,28
The PKC dependence of PAF-induced stimulation of cell adher-
ence agrees with previous reports indicating that PKC regulates
spreading of platelets29 and adhesion of cells to immobilized matrix
proteins.29,30
Direct postreceptor activation of PKC by PMA was not a
sufficient signal to elicit cell aggregation. Our data agree with the
observation that PMA stimulates the integrin a5b1-dependent
adhesion of CHO cells to immobilized fibronectin (Fn) with no
change in Fn binding.31 Similarly, b3 mutations reduced aIIbb3-
dependent stabilization of cell adhesion to Fg without changing
intrinsic Fg-binding affinity.32 Moreover, PMA stimulation of
human megakaryoblastic cells expressing aIIbb3 caused cells to
adhere to immobilized Fg but did not support the binding of soluble
Fg and aggregation.25,33
It is worth noting that CHO-aIIbb3-PAFR cells adhere sponta-
neously to Fg-coated plates and PAF acts in enhancing the rate of
this process. Unlike adherence, in the absence of PAF stimulation
no aggregation was observed in cell suspensions in the presence of
soluble Fg, suggesting that the limited amount of ligand bound
under those conditions is not sufficient to support a significant rate
of cell aggregation. The close relationship found between Fg-
bound and cell-aggregating response supports the conclusion that
PAF-induced aggregation is the result of enhanced binding of Fg
to aIIbb3.
Significance of PAF-induced tyrosine phosphorylation
of proteins
The link between receptor-coupled G proteins and the activation of
aIIbb3 has not been yet elucidated. However, it is currently
accepted that activation of nonreceptor protein tyrosine kinases
(PTKs) and PI3-kinases could play an important role.22,34-36 In
contrast to platelets and in agreement with a previous report,11
inhibition of PTKs by genistein did not prevent the agonist-induced
activation of CHO-aIIbb3-PAFR cells. Whether or not this is
caused by a differential sensitivity of PTKs to genistein or by the
specific inhibition of some phosphatases needs further investiga-
tion. Under our experimental conditions, we detected agonist-
and/or fibrinogen-induced tyrosine phosphorylation of several
proteins. The agonist-induced phosphorylation of FAK was promi-
nent and persistent in cells adhered onto solid-phase Fg and almost
absent in the presence of soluble Fg, in which case the agonist
induced cell aggregation. The pattern of agonist-induced phosphor-
ylation of FAK is consistent with its localization in focal adhesions
and the postulate that ligation of aIIbb3 is not a sufficient signal to
elicit its phosphorylation.37,38 A similar differential effect of
solid-phase or soluble Fg in triggering tyrosine phosphorylation
of FAK has also been reported in the CMK megakaryoblastic
cell line.33
A candidate to mediate the cross talk between PAF and aIIbb3
receptors is the p100-PPA protein. The phosphorylation of p100-
PPA was specifically associated with the engagement of the PAF
receptor and enhanced by the simultaneous occupancy of aIIbb3.
A tyrosine-phosphorylated protein of similar apparent mass has
been observed in human platelets and it was absent in a case of
Glanzmann thombasthenia.39-41 Inhibition of the calcium-calmodu-
lin signaling pathway impeded Fg binding, cell aggregation, and
the phosphorylation of this protein, suggesting a relationship
among these events.
Recombinant PAFR expressed in CHO cells has been reported
to activate MAPK via PTX-sensitive and -insensitive G proteins in
a manner that is not mediated by Ras.42 We observed a marked and
sustained phosphorylation of MAPK distinctly associated with
PAF-induced cell aggregation. Thus, a correlation exists between
phosphorylation of p100-PPA and MAPK and the agonist-induced
aggregation. Since the phosphorylation of these 2 proteins rely
primarily on signals arising from the PAFR and aIIbb3, it seems
plausible to conclude that the PAF-induced aggregation is the result
of coordinated signaling through both receptors.
We failed to detect changes in the phosphorylation of b3
associated with the activation of aIIbb3. A similar finding has been
reported in cells coexpressing aIIbb3 and the fMLP receptor.11 If
these observations could be extrapolated to platelets they would
indicate that phosphorylation of b3 is not needed to initiate platelet
aggregation. This assertion is consistent with the fact that platelets
expressing b3 in which the cytoplasmic tyrosine residues have
been mutated show defective clot retraction but platelet aggrega-
tion was not prevented. Thus, phosphorylation of this subunit may
act primarily in modulating the receptor responsiveness.
To conclude, a physiologic agonist like PAF can activate human
aIIbb3 receptor reconstituted in a rodent cell. In the presence of
immobilized Fg, the PAF-mediated activation of aIIbb3 leads to
PKC-dependent enhancement of cell adherence and spreading
accompanied by parallel changes in the phosphorylation of FAK. In
the presence of soluble Fg, liganded PAFR enables the binding of
PAC1 and enhances the binding of Fg to aIIbb3, leading to
Ca11-calmodulin–dependent cell aggregation and sustained phos-
phorylation of MAPK. The observation that Ca11-calmodulin
inhibitors prevent the PAF-induced binding of Fg to human
platelets suggests that our observations in CHO cells may be of
physiologic significance. In any case, availability of cell lines
coexpressing human aIIbb3 and a surface receptor for a
physiologic agonist offers a sound experimental model to
further investigate the complex interactions between receptors,
ligands, and signaling pathways controlling the state of activa-
tion of platelets.
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